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ABSTRACT
Introduction: In the UK, there is significant variation
in respiratory care and outcomes. An integrated
approach to the management of high-risk respiratory
patients, incorporating specialist and primary care
teams’ expertise, is the basis for new integrated
respiratory services designed to reduce this variation;
however, this model needs evaluating.
Methods: To evaluate an integrated service managing
high-risk respiratory patients, electronic searches for
patients with asthma and chronic obstructive
pulmonary disease at risk of poor outcomes were
performed in two general practitioner (GP) practices in
a local service-development initiative. Patients were
reviewed at joint clinics by primary and secondary care
professionals. GPs also nominated patients for
inclusion. Reviews were delivered to best standards of
care including assessments of diagnosis, control,
spirometry, self-management, education, medication,
inhaler technique and smoking cessation support.
Follow-up of routine clinical data collected at 9-months
postclinic were compared with seasonally matched
9-months prior to integrated review.
Results: 82 patients were identified, 55 attended.
13 (23.6%) had their primary diagnosis changed. In
comparison with the seasonally adjusted baseline
period, in the 9-month follow-up there was an increase
in inhaled corticosteroid prescriptions of 23.3%, a
reduction in short-acting β2-agonist prescription of
33.3%, a reduction in acute respiratory exacerbations
of 67.6%, in unscheduled GP surgery visits of 53.3%
and acute respiratory hospital admissions reduced
from 3 to 0. Only 4 patients (7.3%) required referral to
secondary care. Health economic evaluation showed
respiratory-related costs per patient reduced by
£231.86.
Conclusions: Patients with respiratory disease in this
region at risk of suboptimal outcomes identified
proactively and managed by an integrated team
improved outcomes without the need for hospital
referral.
INTRODUCTION
Long-term respiratory conditions in the UK
are very common; over 6 million people live
with the two most common conditions,
asthma and chronic obstructive pulmonary
disease (COPD).1 Treating respiratory dis-
eases costs the UK National Health Service
(NHS) an estimated £4.7 billion annually.2
Respiratory disease is the third biggest cause
of death in the UK with ∼800 000 patients
dying annually.2 A high proportion of these
costs are generated by a relatively small
group of patients with more severe disease or
with complex problems that include multi-
morbidity, at-risk behaviours and socio-
economic disadvantage.3 4 These patients
often struggle to engage with the structured,
proactive care approach to chronic disease
management advocated for asthma and
COPD, resulting in repeated emergency
healthcare use of primary and secondary
care.4 An integrated approach to the man-
agement of complex patients, incorporating
specialist and primary care teams’ expertise,
may be effective in improving outcomes for
such high-risk patients. However, the evi-
dence is mixed5–8 and there is a need for
evaluations of models of integrated care in
routine, ‘real-world’ clinical settings.
Over the past two decades, there has been
a shift in the locus of care for the majority of
patients with chronic respiratory diseases in
the UK towards the community.9 Respiratory
diseases are among the most common causes
of primary care consultations, accounting
for 24 million consultations annually.10
Increasing numbers of complex respiratory
patients are being managed in the primary
care setting by generalist teams, with a focus
KEY MESSAGES
Integrated respiratory clinics delivering joint care by
specialists and primary care teams can improve
clinical outcomes and reduce care costs for patients
with airways disease.
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on avoidance of admissions to hospital.9 Specialist sec-
ondary care is restricted to those patients admitted to
hospital in a crisis or referred because of uncontrolled
disease.1 10
There is evidence of signiﬁcant and unwarranted vari-
ability in the standards of respiratory management in
the primary and secondary care sectors. Marked varia-
tions in outcomes for patients with respiratory disease
have also been shown, regionally and between individual
general practitioner (GP) practices.1 There is evidence
linking the quality of care provided in general practice
with unplanned admissions to secondary care,11 and
decreased admission rates have been reported in a
number of long-term conditions (including COPD and
asthma) where GPs were ﬁnancially incentivised to
provide high-quality care.12 Moreover, higher levels of
professional education, nurse stafﬁng and clinical
recording in primary care are all associated with an
improvement in the quality of clinical care for patients
with COPD.13 However, a ‘skills gap’ may exist in some
primary care settings, where GPs and other healthcare
professionals lack advanced training in the management
of these common conditions, particularly in the case of
patients with multimorbidity, uncertain diagnosis or
complex problems.14 Patients with more severe or com-
plicated disease may receive suboptimal care, which may
in turn lead to poor outcomes.14 Such patients may fail
to reach a specialist assessment that could potentially
improve outcomes, either because they are not offered
referral to a specialist clinic or because they decline
going to a hospital clinic for such an assessment.
Therefore, a community-based integrated care approach,
harnessing specialist skills and the overall holistic per-
spective of the generalist primary care teams, is a prom-
ising and attractive solution which is being explored by
newly commissioned services. Potential beneﬁts of joint
specialist–generalist clinics in the community include
not only improvement in quality of care for each of the
individual patients seen, but also on-site education for
the primary care teams, leaving a legacy of improved
skills and greater conﬁdence in managing complex
disease.14 Such clinics may potentially increase patient
and staff satisfaction, reduce secondary care use and
consequently reduce the ﬁnancial burden of respiratory
disease on the local health economy.15
Local context
The UK region of Wessex is situated on the south coast
of England and represents a diverse population of
around 2.8 million people, ranging from inner city
deprivation to remote rural populations. Local clinical
audit data have demonstrated marked variation between
local regional administrative groups (eg, a 1.9-fold differ-
ence in COPD admission rates and a 2.8-fold difference
in asthma admission rates) and between individual GP
practices (eg, a 4.7-fold difference in COPD admission
rates). Improving respiratory care is an agreed local pri-
ority and the basis for newly commissioned integrated
respiratory services. West Hampshire Clinical
Commissioning Group (CCG), the Wessex Academic
Health Sciences Network (WAHSN) and the Wessex
Collaboration for Leadership in Applied Health
Research and Care (CLAHRC) collaborated to prospect-
ively evaluate a service pilot of an integrated model for
managing complex or poorly controlled asthma and
COPD across the organisational silos of primary and sec-
ondary care with a view to subsequent regional roll-out.
METHODS
Setting
Two practices were enrolled in the pilot evaluation, one
rural and one urban. Patients with poorly controlled
COPD and asthma were identiﬁed by searches of the
practice clinical computer systems, using routinely
recorded clinical data. The pilot was registered with the
WHCCG as a Quality Improvement project and consult-
ation with the Health Research Authority conﬁrmed the
project to qualify as a service evaluation.
Criteria for patient inclusion and joint-clinic arrangements
COPD patients with poor outcomes were identiﬁed
using four parameters, those measured in the DOSE
Index, a multidimensional assessment tool used to
predict outcomes in COPD16 whose items are routinely
collected in primary care in the UK (Dyspnoea: MRC
Breathlessness Score; Obstruction: % predicted FEV1;
smoking status; exacerbations). Patients with poorly con-
trolled asthma were identiﬁed based on clinical consen-
sus and on at-risk factors identiﬁed by the UK National
Review of Asthma Deaths (NRAD)17 (shown in box 1).
Patients were identiﬁed through the use of electronic
audit and case-ﬁnding tools and a manual review of
routine patient records by respiratory nurse specialists
(RNS). Clinically pertinent information on each patient
was prepared in advance of the clinic including the
number of exacerbations, hospital admissions and
inhaler usage in the 12 months prior to the appoint-
ment. Additionally, clinical staff from the GP practice
were able to include respiratory patients they considered
‘at risk’ or for whom they required further advice or
considered complex.
Patients identiﬁed were invited to attend for a joint
specialist-practice team clinic in the GP premises, includ-
ing diagnostic review and treatment monitoring from
the joint specialist–generalist nursing teams and a clin-
ical assessment from the specialist–generalist medical
teams. The practices agreed to provide administrative
support which included facilitating electronic searches
on their databases, sending out invitations to patients,
booking patients into clinics and reminding patients of
their appointment date and time, much of which is con-
sidered routine clinical practice. There were no ﬁnancial
incentives for the practices. Clinical and information
governance arrangements were agreed: the specialist
respiratory team was endorsed by the CCG as a guest of
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the surgeries and the clinical responsibility for the
patients remained with the GP. No patient identiﬁable
information was removed from the practice premises.
The intervention: collaborative clinics
The clinical intervention consisted of a collaborative
clinic at the patients’ own GP surgery; clinical interven-
tions were driven by clinician–patient interaction rather
than predeﬁned protocol. This comprised a 60 min
appointment including a 20 min initial nurse assess-
ment, including spirometry and other near-patient diag-
nostic and monitoring tests appropriate, by a RNS and a
practice nurse (PN) or nurse practitioner (NP), followed
by a 20 min joint assessment by a respiratory physician
(RP) working alongside a practice clinician (GP and/or
PN/NP) and a 20 min follow-up education session by an
RNS. A personalised disease management and action
plan was agreed jointly between the RP, practice clin-
ician and patient. Practical tasks, for example, prescrip-
tions, were carried out by the practice clinician. Relatives
and carers were actively encouraged to attend with the
patient. The GP retained clinical control and responsi-
bility for the patient.
Outcome measures
Longitudinal follow-up data
Data on exacerbations, medication usage, emergency
department (ED)/hospital admissions and GP practice
visits were collected from the standard practice clinical
electronic records by an RNS 9 months postclinic
(February–November 2015). Data were collected
through a virtual review of routine medical records for
53 patients who still remained on the GP registers. This
was compared to a seasonally matched 9-month period
(February–November 2014) prior to clinic.
Cost-effectiveness analysis
A cost-effectiveness analysis (CEA) of this project was
undertaken: the intervention was the clinic with the out-
comes measured in the longitudinal follow-up (postcli-
nic) data; the comparator was the preclinic data. The
CEA was performed using standard NHS templates for
costing including cost of medication (short-acting
β2-agonist, SABA and inhaled corticosteroid, ICS),
18 cost
of exacerbation (prescription of antibiotic and oral cor-
ticosteroids),18 cost of scheduled and unscheduled GP
and PN visits,19 cost of intervention19 (which included
clinician and administration time and consumables) and
cost of hospital admissions.20
Statistical analysis: paired non-parametric test
Descriptive statistics have been used in the analysis of
the outcome measures. Non-parametric tests (paired
Wilcoxon signed-rank tests) have been calculated on the
non-parametric data to compare the preclinic and post-
clinic data after outcome variables display non-normality
features; the signiﬁcance threshold was 0.05.
Patient and practice feedback
Patients and staff were able to provide unstructured
written feedback on the service at the end of their
appointment. Feedback was not formally requested from
the integrated care team, however a debrieﬁng and edu-
cation session was held following the completion of the
clinics which provided an outlet for feedback from the
team members.
RESULTS
GP practice demographics
Two GP practices were included in this pilot project.
The ﬁrst was a large, rural market town practice with a
practice population of 12 598, staffed by 10 GPs, 3 NPs,
2 PNs and 3 healthcare assistants (HCAs). The practice
population deprivation is in the second least deprived
decile in the UK; the COPD and asthma prevalence at
baseline was 1.8% and 6.7%, respectively (compared to
a Wessex average of 1.7% for COPD and 6.3% for
asthma). The second was a small, suburban practice with
a practice population of 3604 staffed by 1 GP, 1 NP, 2
PNs and 1 HCA. The practice population deprivation is
in the fourth least deprived decile in the UK; the base-
line COPD and asthma prevalence was 1.7% and 4.6%,
respectively.
Box 1 Inclusion and exclusion criteria for identifying
patients for clinics
Inclusion criteria for identifying patients with complex asthma
▸ High use of short-acting β2-agonist/inhaled corticosteroid
combinations (<12 in 12 months).
▸ High SABA use (>12 in 12 months).
▸ High SABA use, low ICS use (>12 SABA and <12 ICS in
12 months).
▸ High oral corticosteroid use (>2 prescriptions for prednisolone
in 12 months).
▸ High doses of ICS monotherapy (≥800 mcg of budesonide
(or equivalent)).
Inclusion criteria for identifying patients with complex chronic
obstructive pulmonary disease
▸ Exacerbations within the last 12 months.
▸ Acute hospital admissions related to respiratory within the last
12 months.
▸ MRC≥3.
▸ FEV1<50% predicted.
▸ At the GP/practice nurse’s discretion.
Exclusion criteria
▸ Pregnancy.
▸ Housebound.
▸ Under secondary care for respiratory issue (or other related,
eg, cardiac for breathlessness).
▸ Active cancer.
▸ At the GP’s discretion.
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Patient demographics
Eighty-two patients were invited to the intervention
clinics, shown in ﬁgure 1. Fifty-six of these patients
responded and booked an appointment. Of all patients
who booked an appointment, 98.2% (55) attended the
clinics. Demographics for these patients are shown in
table 1.
Clinic data
Diagnostic review and accuracy
Of the 55 patients seen in the complex clinics, 13
(23.6%) received a change in diagnosis after review by
the clinical project team (ﬁgure 2A). Reasons for this
change in diagnosis included inaccurate initial diagno-
sis; condition changing over time, for example, asthma
to Asthma and COPD overlap syndrome (ACOS); a
correct diagnosis had been made previously but not
been recorded in the electronic record; the necessary
differential diagnostic tests had not been performed to
identify the condition.
Onward referrals
Of the 55 patients seen, only 4 (7.3%) were referred on
to secondary care for further investigations. Thirty-seven
(67.3%) required further appointments with their GP/
PN for follow-up care such as medication reviews or
inhaler technique checks. The remaining 14 (25.4%)
did not require any follow-up and returned to the usual
routine care with their GP/PN.
CLINICAL OUTCOME: LONGITUDINAL FOLLOW-UP DATA
(POSTCLINIC).
Medication usage
SABA inhalers
The number of prescribed SABA inhalers over a
9-month period (February–November 2014) prior to the
joint clinic ranged from 0 to 30, with a median of
5. Following the joint clinic, the number of prescribed
SABA inhalers ranged from 0 to 26, with a median of 3
over a 9-month period (February–November 2015). The
total number of SABA prescribed over the 9-month
periods reduced by 33.3% (427 to 285), p<0.001 (see
ﬁgure 2B). The frequency of prescriptions is shown in
ﬁgure 3A.
ICS inhalers
The total number of ICS-containing inhalers prescribed
for all patients increased by 23.3% (295–364), p<0.05 in
Table 1 Demographics of patients attending clinics
N (%)
Patients attended 55
Mean age 60
Age range 19–82
Females 33 (60%)
Patients with follow-up data 53
Baseline diagnosis 55
Asthma 36 (65%)
COPD 7 (13%)
Asthma and COPD overlap syndrome (ACOS) 9 (16%)
‘Other respiratory’ 1 (2%)
No respiratory diagnosis 2 (4%)
Smoking data 53
Current smoker 11 (21%)
Ex smoker 22 (42%)
Never smoker 20 (38%)
Body mass index (BMI) data 53
BMI <20 0
BMI 20–24 13 (25%
BMI 25–29 20 (38%)
BMI 30–39 18 (24%)
BMI ≥40 2 (4%)
Figure 1 Patient identification, attendance and diagnosis
data. ACOS, Asthma and COPD overlap syndrome; COPD,
chronic obstructive pulmonary disease.
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the 9 months following the specialist clinic compared to
the previous seasonally matched 9-month period. A sub-
analysis of the 28 patients with asthma, in whom ICS
adherence is particularly important, was performed,
shown in ﬁgure 3B. The number of ICS inhalers pre-
scribed over a 9-month period prior to the joint clinic
ranged from 0 to 24, with a median of 5. The number of
ICS inhalers prescribed over a 9-month period following
the joint clinic ranged from 0 to 18, with a median of
6.5.
Healthcare usage
In the seasonally matched 9-month period preclinic and
postclinic, respiratory exacerbations (deﬁned as a non-
scheduled contact caused by an acute deterioration in
respiratory symptoms resulting in a prescription of oral
steroids and/or antibiotics, with a continuation of symp-
toms without improvement requiring multiple courses of
treatment classed as one exacerbation) reduced by
67.6% (from 37 to 12), p<0.01 (ﬁgure 4). Non-elective
respiratory GP visits (deﬁned as an urgent, unplanned
respiratory appointment with the GP) reduced by 78.5%
(from 42 to 9), p≤0.01. Elective respiratory GP visits
(deﬁned as planned respiratory appointments with the
GP for reasons such as medication reviews and clinical
review following resolution of an exacerbation) reduced
by 28.6% (from 28 to 20), p<0.05. Respiratory PN visits
reduced by 47.7% (from 65 to 34), p<0.01. In total, the
number of visits to the GP surgery for respiratory issues
was reduced by just over half (from 135 to 63), p<0.01.
In the seasonally matched 9-month period preclinic
and postclinic, the number of admissions or ED atten-
dances for respiratory issues reduced from 3 to 0,
p<0.05. At the time of the follow-up review in November
2015, none of the patients who attended the specialist
clinics had died.
Health economic evaluation
Respiratory-related costs per patient over a 9-month
period decrease from £458.11 to £226.25 following the
intervention, a reduction of £231.86 per patient, equat-
ing to an annualised saving of £309.15 (table 2). The
overall cost of the intervention for the 55 patients seen
in two practices was £16 325 equating to £296.82 per
patient. The incremental cost-effectiveness of the inter-
vention versus no intervention is £142.89 per exacerba-
tion avoided (considered as cost per patient in the
timeframe of 9 months).
Patient feedback
Of the 55 patients who attended, 50 provided unstruc-
tured written feedback on the service. All described
attending the clinics as a positive experience in terms of
patient experience of the clinic and interventions made.
Feedback from practices
The informal feedback received from the integrated
team members was also extremely positive. Specialist
and generalist clinicians found it a useful learning
experience with an immediate impact on practice. For
example, GPs and PNs stated that they approached
inhaler technique training differently after the clinic.
RPs mentioned changing the way in which they dissemi-
nated information to primary care to include more
detailed information.
DISCUSSION
Main findings
We present ﬁndings from a prospective evaluation of a
local service development consisting of an integrated
Figure 2 Impacts of clinical review. (A) Summary of changes
in clinical diagnosis after clinic review. (B) Summary of inhaled
short-acting bronchodilator and inhaled corticosteroid
prescription in 9 months prior to and after clinical review. ACOS,
Asthma and COPD overlap syndrome; COPD, chronic
obstructive pulmonary disease; OSA, obstructive sleep apnoea.
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model of care aiming to improve outcomes for complex
respiratory patients in the community. The model
involved identiﬁcation of patients with poor outcomes
and their review in joint clinics delivered collaboratively
by visiting specialist teams and the host primary care
teams. This initiative was acceptable to patients and
healthcare professionals, including members of the inte-
grated care team. The project demonstrated that inform-
atics approaches to identiﬁcation of patients with poorly
controlled respiratory disease and follow-up is possible
and may be conducted using electronic searches of
routine clinical data from medical records. Moreover,
Figure 3 Change in frequency
of SABA and ICS prescription
after clinical intervention. (A)
Frequency of SABA prescriptions
preclinic and postclinic (n=53). (B)
Frequency of ICS inhaler
prescriptions for patients with
asthma preclinic and postclinic
(n=28).
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this intervention can improve both markers of efﬁcient
medication use such as improved adherence to pre-
venter inhaled therapy and reduced use of rescue medi-
cation and in improved markers of clinical outcomes
such as frequency of exacerbation and unscheduled
primary care consultations. The health economics ana-
lysis demonstrates signiﬁcant cost savings over usual
respiratory care that may cover the additional costs of
providing the service, although this will require conﬁrm-
ation in larger studies with a more rigorous health eco-
nomic evaluation and longer follow-up periods.
The acceptability of the intervention to patients is not
only demonstrated through the positive feedback but
also by the high response and attendance levels. Some
of the patients who attended had repeatedly failed to
attend the practice for their routine asthma/COPD
annual check-up, a risk factor for exacerbations and pre-
mature mortality.17 The high level of attendance to the
joint respiratory clinics suggests that patients may be
more motivated to attend specialist respiratory clinics
located in GP surgeries rather than, conventionally, at
their local hospital thus potentially providing a more
acceptable, efﬁcient and cost-effective service. However,
several issues remain—more work is required to identify
optimal mechanisms to identify patients with inadequate
control and at greatest risk of poor outcome.
Furthermore, work is required to address the real unmet
need driven by frequent no-attenders to clinical review
in routine primary care and in additional services such
as this. This population similarly is not involved in
current service evaluations and focused research in this
group is needed.
The intervention resulted in a change in primary diag-
nosis for almost a quarter of the patients who attended the
clinic. Improving diagnostic accuracy relied particularly on
the provision of quality assured spirometry and where
needed additional near-patient tests (eg, fraction of
exhaled nitric oxide testing). Accurate diagnosis is funda-
mental to the appropriate provision of preventive
therapy,21 enabling appropriate management tailored to
Table 2 Health economic evaluation of clinics: cost per
patient over a 9-month period
Cost preclinic Cost postclinic
GP visit £85.27 £35.33
PN visit £52.00 £27.20
SABA £29.37 £19.60
ICS £116.16 £143.32
Exacerbations £2.44 £0.79
Hospital admissions £172.88 £0.00
Total cost £458.11 £226.25
GP, general practitioner; PN, practice nurse; SABA, short-acting
β2-agonist.
Figure 4 Number of
exacerbations, emergency
hospital admissions and primary
care visits before and after clinics.
ED, emergency department; GP,
general practitioner.
Gillett K, Lippiett K, Astles C, et al. BMJ Open Resp Res 2016;3:e000145. doi:10.1136/bmjresp-2016-000145 7
Open Access
each condition, for example, ICS in asthma and pulmon-
ary rehabilitation in COPD, and may help to avoid treat-
ment that is of no beneﬁt or harmful.22 The shift shown in
prescription patterns after clinic review was to one more
closely aligned with national guidelines for both COPD.
The majority of patients had either a change in diagnosis
and/or management made without the need for further
input from secondary care, which demonstrates the prac-
ticability of this integrated care model in primary care.
Prevention of exacerbations is a key goal in improving
control of COPD and asthma.23 24 Furthermore, reducing
hospital admissions has potential cost savings for the NHS.
Emergency hospital admissions for ambulatory care sensi-
tive conditions (ACSC) cost the NHS £1.42 billion annu-
ally; 34% of these are for respiratory-related disease.25 The
results from this project show a reduction in healthcare
usage both in terms of exacerbations, hospital admissions
and GP surgery attendance. A 68% reduction in exacerba-
tions and 79% reduction in non-elective GP visits are par-
ticularly worthy of note and indicate better disease
control. The health economic analysis demonstrated that
there was a cost saving in terms of healthcare usage follow-
ing the intervention. Further research with a longer
follow-up period is needed to perform an analysis of
whether the outcomes from the intervention, for example,
reductions in healthcare usage, are sustainable and
whether the model will have further cost savings long term
as beneﬁts continue to accrue. Further research will also
require the collection of quality of life data in order to cal-
culate the cost-effectiveness in terms of cost per
quality-adjusted life year (QALY).
This integrated model allowed for shared learning
interorganisationally, between primary and secondary
care, and intraorganisationally, within the multidisciplin-
ary team. Furthermore, this initiative placed a strong
emphasis on the importance of patient and carer educa-
tion. The emphasis on education for patients, carers and
healthcare professionals was intended to leave a legacy
of patients who are able to self-manage more effectively
and healthcare professionals who are upskilled in the
management of patients with respiratory disease and
more technically assured in performing specialist
respiratory assessments.
Interpretation of findings in relation to previously
published work
This project has demonstrated that this integrated
model of care has the potential to improve outcomes for
patients with complex respiratory conditions. This is sup-
ported by evidence from various NHS organisations
including NHS England26 and the King’s Fund,14 which
suggest that ensuring specialist support in the delivery of
care outside hospital has the potential to improve
patient experience and access to care.
Strengths and limitations
The beneﬁts of this intervention in terms of improving
patient outcomes and experience, access to care and
reduction in healthcare usage were signiﬁcant and have
the potential to be replicated across the NHS, but
require replication in large, well-designed trials. Formal
research in a controlled setting (eg, an appropriately
powered cluster randomised trial, comparing outcomes
in matched practices receiving and not receiving the
outreach intervention) is needed.
The intervention in this pilot was a complex and
multifactorial one. Consequently, understanding which
aspects of the process were key drivers to improvement
in an individual is difﬁcult to ascertain; this issue is exa-
cerbated by the relatively small sample size and that
patients with asthma and patients with COPD were
reviewed. Future larger scale studies and more discrete
interventions may be required to tease out relative bene-
ﬁts of diagnostic change from treatment alterations or
improved adherence. A more pragmatic approach would
be to improve the evidence base behind the improved
delivery of guideline adherent care in an integrated
team and hence to provide the rationale for commis-
sioners to adopt this model at scale if proven to be
cost-effective.
The limited sample size in this pilot restricts the
power to detect signiﬁcant change in hospital admis-
sions, a major driver to costs in respiratory care.
However, a reduction was observed, which will again
need further investigation in larger controlled trials.
Implications for future research, policy and practice
Future research in a controlled environment to prove a
causal relationship between this integrated respiratory
care model and an improvement in respiratory out-
comes in a cluster randomised trial is required. If vali-
dated this model will then have the potential to be
replicated across the NHS and improve respiratory out-
comes for patients throughout the UK.
CONCLUSIONS
A range of evidence demonstrates that the current react-
ive model predicated on acute hospitals is unsustainable
in the face of an ageing population, with increasingly
complex chronic conditions. This service-development
evaluation demonstrates that patients with respiratory
disease at risk of suboptimal outcomes can proactively
be identiﬁed for management by an integrated team in
the community without the need for extensive, expen-
sive secondary care technologies and warrants further
evaluation at scale to determine its impact in other
regions to fully determine health economic outcomes.
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